Can 3D-printed medical implants boost strength, reduce costs?

3D printing has expanded into the field of implantable medical devices by making them more personalized, stronger and at a reduced cost. Researchers from the University of Florida published recent findings on a new 3D process in Science Advances.

The new technique uses a combination of 3D printing and silicone to develop ports for draining bodily fluids, implantable bands, balloons, soft catheters, slings and meshes. Researcher hope the new process will improve current therapeutic devices that control and release drugs.

"Our new material provides support for the liquid silicone as it is 3D printing, allowing us create very complex structures and even encapsulated parts out of silicone elastomer," said lead author Christopher O'Bryan, a mechanical and aerospace engineering doctoral student in UF's Herbert Wertheim College of Engineering.

Current production of implantable medical devices involves waiting weeks for customized molds that are often expensive. With the 3D printing method, researchers are able to create stronger molds in hours with enough precision of smaller complex devices.

"The reality is that we are probably decades away from the widespread implanting of 3D-printed tissues and organs into patients," said team member Tommy Angelini, an associate professor of mechanical and aerospace. "By contrast, inanimate medical devices are already in widespread use for implantation. Unlike the long wait we have ahead of us for other 3D bioprinting technologies to be developed, silicone devices can be put into widespread use without technologically limited delay."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.